Open AccessAlzheimer’s Disease: Pharmacotherapy of subjective cognitive decline
Author(s) -
Aslam Pathan,
Abdulrahman Alshahrani
Publication year - 2018
Publication title -
neuropharmac journal
Language(s) - English
Resource type - Journals
ISSN - 2456-3927
DOI - 10.37881/1.321
Subject(s) - dementia , apraxia , cognition , cognitive decline , aphasia , disease , agnosia , psychology , pharmacotherapy , medicine , psychiatry , clinical psychology , neuroscience , pathology
Alzheimer's disease (AD) is a neurodegenerative disorder marked by cognitive and behavioral impairment that significantly interferes with social and occupational functioning. AD is progressive and fatal dementia of unknown cause characterized by loss of cognitive and physical functioning, commonly with behavior or cognitive symptoms. Cognitive decline is gradual and includes memory loss, aphasia, apraxia, agnosia, disorientation, and impaired executive function. physicians will often play a major role in diagnosing and treating dementia and related disorders in the community. Accurate treatment of cognitive symptoms is important. Accordingly, we reviewed the available pharmacotherapy in the clinical management of cognitive symptoms of dementia.